Background: Incontinentia pigmenti (IP; MIM308300) is a severe, male-lethal, X-linked, dominant genodermatosis resulting from loss-of-function mutations in the IKBKG gene encoding nuclear factor kB (NF-kB) essential modulator (NEMO; the regulatory subunit of the IkB kinase [IKK] complex). In 80% of cases of IP, the deletion of exons 4 to 10 leads to the absence of NEMO and total inhibition of NF-kB signaling. Here we describe a new IKBKG mutation responsible for IP resulting in an inactive truncated form of NEMO. Objectives: We sought to identify the mechanism or mechanisms by which the truncated NEMO protein inhibits the NF-kB signaling pathway. Methods: We sequenced the IKBKG gene in patients with IP and performed complementation and transactivation assays in NEMO-deficient cells. We also used immunoprecipitation assays, immunoblotting, and an in situ proximity ligation assay to characterize the truncated NEMO protein interactions with IKK-a, IKK-b, TNF receptor-associated factor 6, TNF receptor-associated factor 2, receptor-interacting protein 1, Hemo-oxidized iron regulatory protein 2 ligase 1 (HOIL-1), HOIL-1-interacting protein, and SHANK-associated RH domain-interacting protein. Lastly, we assessed NEMO linear ubiquitination using immunoblotting and investigated the formation of NEMO-containing structures (using immunostaining and confocal microscopy) after cell stimulation with IL-1b.
Incontinentia pigmenti (IP; MIM308300) is a severe, malelethal, X-linked dominant genodermatosis. It is characterized by the occurrence of Blaschko linear skin lesions during the neonatal period in 4 successive stages: erythema, vesicles, pustules (stage 1), verrucous lesions (stage 2), hyperpigmentation (stage 3), and atrophy (stage 4). 1 Neonatal rashes can be associated with developmental anomalies of the teeth, eyes, hair, and central nervous system. [2] [3] [4] Early lethality in male patients with IP and complete skewing of X-inactivation in female patients with IP unequivocally result from null loss-of-function mutations in the IKBKG gene coding for nuclear factor kB (NF-kB) essential modulator (NEMO/IkB kinase [IKK] g), the regulatory subunit of the IKK complex and a core component of the NF-kB cascade. The downstream effector NF-kB is an ubiquitous transcription factor involved in many physiologic functions, including inflammatory and immune responses, apoptosis, cell survival, and embryonic development. 5, 6 Seventy percent to 80% of patients with IP carry a common genomic rearrangement that results in deletion of exons 4 to 10 of the IKBKG gene. [7] [8] [9] Most of the other IP-associated IKBKG mutations identified to date are truncating mutations that result in complete inhibition of the NF-kB signaling pathway. Hypomorphic nonlethal missense mutations in IKBKG result in residual NF-kB activity and can cause isolated immunodeficiency or anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) syndrome. The latter syndrome is combined with osteopetrosis and lymphedema in some cases and is isolated in other cases. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] In resting cells NF-kB is trapped in the cytoplasm by inhibitory molecules from the IkB family. In response to a variety of stimuli (eg, IL-1b, bacterial LPS, and proinflammatory cytokines, such as TNF-a), the IKK complex is activated and phosphorylates the inhibitory IkB proteins. The latter are then rapidly ubiquitinated and degraded by the 26S proteasome machinery. This subsequently enables the NF-kB transcription factor to translocate into the nucleus and regulate target gene transcription. 5, 21, 22 It has recently been shown that NEMO is rapidly and transiently recruited into punctuate structures on stimulation by TNF-a or IL-1b. 23 The latter are enriched in activated IKK kinases and ubiquitinated NEMO molecules. Furthermore, to the K63-linked polyubquitination of NEMO, 24 it has been demonstrated recently that a novel type of head-to-tail linked linear polyubiquitination is also critical for regulation of the NF-kB pathway. [25] [26] [27] [28] [29] Linear polyubiquitination is mediated through the linear ubiquitin assembly complex (LUBAC), a 600-kDa ubiquitin ligase ternary complex composed of hemo-oxidized iron regulatory protein 2 ligase-1 (HOIL-1), HOIL-1-interacting protein (HOIP), and SHANK-associated RH domain-interacting protein (SHARPIN).
In the present study we generated functional data on fibroblasts derived from a male fetus with IP carrying a c.51812T>G splice mutation in the IKBKG gene. We found that loss of the NEMO-SHARPIN interaction impaired recruitment of truncated NEMO forms into punctuate structures that are transiently formed on cell stimulation and thus led to a defect in linear ubiquitination. Our results highlight a novel disease mechanism in patients with IP.
METHODS

Case reports
Carrier female subjects and most of their unaffected relatives underwent a full clinical examination. All female patients with IP met the 1993 revised criteria for the classification of IP. The female patients with IP had a history of perinatal blistering and at least 1 of the other skin lesion stages. Several early spontaneous abortions were reported, although most had not been investigated further. Biological material was only collected after the patients had given their written informed consent in accordance with the tenets of the Declaration of Helsinki.
Plasmid constructions
Human cDNA containing the entire open reading frame or truncated cDNA of NEMO was amplified, respectively, from control RNA or fibroblast RNA from a male fetus with IP. The amplified DNAwas then cloned into the pcDNA 3.1 expression vector, with either a hemagglutinin (HA) epitope or a FLAG epitope N-terminal tag.
Reagents
The following antibodies were used: anti-NEMO (BD Biosciences PharMingen, San Jose, Calif), anti-IkBa (sc-371; Santa Cruz Biotechnology, Dallas, Tex), anti-IKK-a (BD Biosciences PharMingen), anti-IKK-b (BD Biosciences PharMingen), anti-RIP (BD Biosciences PharMingen), anti-TNF receptor-associated factor (TRAF) 6 (sc-7221, Santa Cruz Biotechnology), anti-TRAF2 (sc-876, Santa Cruz Biotechnology), anti-SHARPIN (14626-1-AP; Proteintech, Rosemont, Ill), anti-V5 (Sigma-Aldrich, St Louis, Mo), anti-FLAG (Sigma-Aldrich), and anti-HA (Sigma-Aldrich). The specific human antibody against linear polyubiquitin chains (1F11/3F5/Y102L) was provided by Genentech (South San Francisco, Calif).
Fibroblast stimulation and IL-8/IL-6 production
Control and patient-derived fibroblasts were immortalized by means of transfection with a plasmid encoding the SV40 large T antigen. Transformed cell lines were grown in Dulbecco modified Eagle medium (Invitrogen, Carlsbad, Calif) supplemented with 10% FCS (Invitrogen). Immortalized cells were grown in 24-well plates and incubated with 10 ng/mL IL-1b or TNF-a (R&D Systems, Minneapolis, Minn). Twenty-four hours after stimulation, supernatants were collected, and IL-8 or IL-6 production was assessed with an ELISA, according to the manufacturer's instructions (Sanquin, Amsterdam, The Netherlands).
Immunoprecipitation
HEK293T cells (2 3 10 6 ) were transiently transfected (with jetPRIME reagent; Polyplus-transfection, New York, NY) with mutant or wild-type NEMO constructs (2 mg per dish) and various partners of interest (2 mg). Twenty-four hours after transfection, cells were lysed in special buffer (50 mmol/L Tris-HCl [pH 8], 170 mmol/L NaCl, 0.5% NP-40, and 50 mmol/L NaF) with protease inhibitors (Roche Diagnostics, Mannheim, Germany). Immunoprecipitation was performed with the mMACS HA Isolation Kit or mMACS protein G Microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). Bound antibodies were visualized with horseradish peroxidase-conjugated antibodies against rabbit or mouse IgG (Santa Cruz Biotechnology, Heidelberg, Germany) and the Enhanced Chemiluminescence Kit with SuperSignal West Dura Extended Duration Substrate (Thermo Scientific, Rockford, Ill).
Immunofluorescence
Cells cultured on glass coverslips were treated twice with ice-cold saponin extraction buffer (80 mmol/L PIPES [pH 6.8], 1 mmol/L MgCl 2 , 1 mmol/L EGTA, and 0.1% saponin) for 2 and 4 minutes on ice, as previously described. 23 Cells were then washed twice with PBS before fixation in 100% methanol. Cells were progressively rehydrated by means of successive washes with 85%, 70%, and 50% ethanol in water and 2 final washes with PBS. For linear polyubiquitin staining, slides were treated with vOTU deubiquitinase (1 hour at 378C). This eliminates unspecific interactions with the anti-linear ubiquitin chain antibody because vOTU cleaves all ubiquitin chain linkages other than linear chains. After blocking by means of incubation with 1% BSA in PBS, slides were incubated with rabbit anti-SHARPIN, mouse anti-NEMO, or human anti-linear polyubiquitin antibody; washed with PBS; and incubated either with anti-rabbit Alexa Fluor 488 or anti-human Alexa Fluor 546 secondary antibodies (Life Technologies, Grand Island, NY). Slides were washed again and incubated with 49-6-diamisino-2-phenylindole dihydrochloride (Sigma-Aldrich) to stain the nuclei. Coverslips were mounted in Mowiol supplemented with an anti-fading agent (AF100; Biovalley). Image acquisition was performed with the Zeiss LSM 700 (Carl Zeiss Microscopy GmbH, Oberkochen, Germany) and Zen software (Carl Zeiss Microscopy GmbH). For quantification of NEMO, SHARPIN, and linear ubiquitin foci, randomly selected fields acquired with a 3 63 objective lens and Z-stack were processed with ICY open source software and the Spot Detector tool (icy.bioimageanalysis.org/).
Statistical analysis
Results were expressed as means 6 SDs. Statistical significance was determined by using unpaired 2-sample equal-variance t tests. All data were normally distributed, and the variance was similar in all compared groups. The threshold for statistical significance was set to a P value of less than .05.
Additional methods
The procedures used in this study are described in detail in the Methods section in this article's Online Repository at www.jacionline.org.
RESULTS
Genetic and functional analyses of the truncated NEMO protein
We assessed a large IP kindred segregating over 3 generations. All the affected female subjects had a skewed X-inactivation pattern (Fig 1, A) and presented with typical IP-associated skin lesions. Female subject II.3 also had right hemiplegia. Female subject II.8 had a history of seizures during infancy, persistent migraine attacks, and 2 early spontaneous abortions (before 10 weeks of gestation). During the second of these pregnancies (III.4), an indirect molecular diagnosis (using DNA extracted from chorionic villus samples) identified the haplotype that segregated with IP disease in the family. A therapeutic abortion was performed. Fibroblasts from a skin biopsy specimen of the affected male fetus were then cultured. We identified a splice donor site mutation in IKBKG exon 4 (c.51812T>G; Fig 1, B) , which segregated with the disease in the whole kindred. RT-PCR and then direct sequencing of RNAs from the affected male fetus's cultured skin fibroblasts confirmed the presence of the c.51812T>G mutation, which resulted in skipping of exons 4 to 6 (Fig 1, C and D) . The c.51812T>G mutation is predicted to produce a truncated protein that lacks part of the coiled-coil motif (CC1) and the NEMO linker (the HLX2 helical domain) but retains the C-terminal part of NEMO (Fig 1, E) . Indeed, Western blot analyses confirmed the presence of a truncated NEMO protein with a molecular weight of about 32 kDa.
The resulting truncated NEMO protein (p.DelQ134_R256) thus contained all the essential domains. The deletion introduces a novel junction between Q133 (CC1) and G257 (CC2-LZ), which probably causes a discontinuity in the regular heptad repeats of the CC1 and CC2-LZ domains and might thus impair oligomerization. Furthermore, the shortened superhelical coiled-coil structure is predicted to change the orientation of the ubiquitin-binding NEMO-optineurin-ABIN domain (also referred as to UBAN and NUB) relative to the IKK-b binding site, as indicated in Fig 2 and As observed in fetal fibroblasts carrying the common IKBKG deletion (Del exons 4-10, Fetus NEMO 2/27 ), fibroblast cells carrying the c.51812T>G IKBKG mutation displayed severely impaired IkBa degradation after TNF-a and IL-1b stimulation (Fig 3, A) . Analysis (by using ELISAs) of the secreted NF-kB target proteins showed that fibroblasts carrying the c.51812T>G IKBKG mutation produced neither IL-6 nor IL-8 on stimulation by TNF-a and IL-1b (Fig 3, B) .
To determine whether impaired NF-kB signaling was due to protein truncation alone or to putative NEMO isoforms resulting from the splice mutation, we subcloned the wild-type and truncated NEMO constructs and performed transactivation experiments in Ikbkg 2/2 mouse embryonic fibroblasts. The truncated p.DelQ134_R256 NEMO isoform was unable to activate NF-kB in response to either TNF-a or IL-1b (Fig 3,  C) , demonstrating that this event was sufficient for the complete inhibition of NF-kB activity. Hence the c.51812T>G genotype is a loss-of-function IKBKG mutation that inactivates the NEMO protein and impairs the NF-kB signaling pathway.
Integration of the truncated NEMO protein into the IKK complex, K63 polyubiquitination, and oligomerization
After transfection of HEK293T cells with various combinations of constructs, immunoprecipitation (with anti-IKK-a or anti-IKK-b antibodies) and Western blot analyses (using an anti-HA antibody) showed that HA-tagged truncated NEMO protein was correctly integrated into the IKK complex (Fig 3, D) . Furthermore, immunoprecipitation (with specific antibodies against receptor-interacting protein 1 (RIP1), TRAF2, and TRAF6) and immunoblotting (with an anti-HA antibody) showed that the truncated NEMO species was also able to interact with RIP1, TRAF2, and TRAF6, all of which are known to be required for NF-kB activation by TNF-a (RIP1 and TRAF2) or IL-1b (TRAF6; Fig 3, E) . In the latter experiment the same results were obtained when immunoprecipitation was performed with an anti-HA antibody and immunoblotting was performed with the specific antibodies (Fig 3, E) . It is noteworthy that TRAF6 is an E3 ubiquitin ligase required for NF-kB activation and that it catalyzes the K63-linked polyubiquitination of NEMO.
Cotransfection of HEK293T cells with NEMO plasmids and plasmids expressing ubiquitin in the presence of TRAF6 resulted in a similar K63-linked polyubiquitination pattern for both the truncated and wild-type NEMO proteins (Fig 3, F) . In contrast, homodimerization/oligomerization of the truncated NEMO proteins was less intense (relative to control experiments) when FLAG-NEMO and HA-NEMO were cotransfected into HEK293T cells, immunoprecipitated with an anti-FLAG antibody, and immunoblotted with an anti-HA antibody (Fig 3, G) .
NEMO/LUBAC interaction
We next assessed the interaction between HA-tagged wild-type NEMO or truncated NEMO proteins and each of the 3 LUBAC subunits (HOIL-1, HOIP, and SHARPIN). Immunoprecipitation (with an anti-HA antibody) and immunoblotting (with anti-FLAG or anti-V5 tag antibodies) showed that wild-type NEMO interacted with all 3 human LUBAC subunits. In contrast, the truncated NEMO interacted with HOIL-1 and HOIP but not with SHARPIN (Fig 4, A) .
To further characterize the interaction between NEMO and SHARPIN in cells, we used the Duolink II in situ proximity ligation assay (PLA); this is a highly specific and sensitive technique for detecting protein colocalization/interactions through the generation of localized spot signals. 30 An in situ PLA performed on transfected cells also provides the exact position of the recognition event. The maximum distance between 2 signal-producing epitopes ranges from 10 to 30 nm. Our PLA results showed that wild-type NEMO interacts directly with SHARPIN and HOIL-1 but not with HOIP (in contrast to the above-mentioned immunoblot results ; Fig 4, A; see the Discussion section). The truncated NEMO form was also able to interact with HOIL-1 but did not bind to SHARPIN (Fig 4, B) , thus confirming the immunoblot results in this respect.
Formation of supramolecular NEMO-containing complexes and linear ubiquitination in the patients' fibroblasts in response to IL-1b
Recently, we showed that the activated IKK complex is rapidly and transiently reorganized into supramolecular complexes in response to stimulation by cytokines, such as IL-1b (marking the earliest steps of NF-kB activation). 23 Therefore we used immunostaining and confocal microscopy to investigate the formation of NEMO-containing structures in cells from patients with IP on IL-1b stimulation. We found that the IL-1b-induced formation of NEMO-containing structures was impaired in (1) fibroblasts from fetus III.4 with IP carrying the truncated NEMO form (Del 134_326), (2) fibroblasts from a fetus with IP carrying the frequent IKBKG gene rearrangement (Del exons 4-10, NEMO 2/2 ), and (3) recently characterized HOIL-1-deficient fibroblasts from patients without IP (Fig 5, A) . As expected, stimulation of control cells with IL-1b yielded dots of NEMO-and SHARPIN-containing supramolecular structures. In contrast, the IL-1b-induced recruitment of these supramolecular complexes was impaired in cultured fibroblasts obtained from various patients with IP (Fig 5, A) . Furthermore, quantification of the immunostained dots revealed low levels of SHARPIN in fibroblasts carrying the truncated form of NEMO (relative to fibroblasts from healthy control subjects; Fig 5, B) . The same results were found in HOIL-1-deficient fibroblasts and in NEMO-deficient IP cells carrying the IKBKG gene rearrangement. Moreover, immunoblot assays revealed low expression levels of HOIL-1, HOIP, and SHARPIN in cells from fetus III.4 with IP (relative to control cells; Fig 5, C) . Quantitative RT-PCR analyses showed that mRNA levels expression of the 3 LUBAC subunits are similar in fibroblasts from fetus III.4 with IP and control subjects (Fig 5, D) .
Lastly, we used immunofluorescence assays with a recently engineered anti-linear ubiquitin chain antibody to examine the formation of linear polyubiquitin chains in IL-1b-treated fibroblasts carrying the truncated NEMO form. 31 Interestingly, we found that linear polyubiquitin aggregates colocalized with NEMO in IL-1b-treated control cells (Fig 6, A) . These aggregates were weakly present in cells from patients with IP and in HOIL-1-deficient fibroblasts from patients without IP. Quantification of NEMO and linear ubiquitin chains confirmed these observations (Fig 6, B) . Cotransfection of HEK293T cells with NEMO plasmids and plasmids encoding ubiquitin K0 (all lysine residues were replaced by arginine) and LUBAC subunits showed a defect of linear ubiquitination of the truncated NEMO protein (Fig 6, C) . These findings suggest that perturbation of the NEMO-SHARPIN interaction impairs linear ubiquitination of NEMO.
DISCUSSION
Here we showed that a novel IKBKG splice-site mutation in an affected male fetus from a large IP kindred resulted in truncation of the NEMO protein CC1 and HLX2 domains. The truncated form of NEMO dimerizes/oligomerizes less readily than the wild-type. Moreover, the interaction between the truncated NEMO protein and SHARPIN is specifically impaired and results in defective linear ubiquitination. In contrast, the truncated NEMO protein interacted normally with HOIL-1, HOIP, RIP1, TRAF2, and TRAF6. K63-linked polyubiquitination of truncated NEMO by TRAF6 was normal, and the mutant protein was still recruited into the IKK complex.
Transfection/immunoprecipitation assays and PLAs provided evidence of loss of interaction of the truncated form of NEMO with SHARPIN and maintenance of the interaction with HOIP and HOIL-1. Given that the PLAs did not provide any evidence of a close interaction between wild-type NEMO and HOIP (in contrast to the immunoblots), we suggest that these 2 proteins interact through SHARPIN, HOIL-1, or ubiquitin chains in human subjects. This would differ from the situation in mice, where HOIP binds directly to NEMO through the HOIP NZF1 domain. Moreover, we found that the IL-1b-induced formation of NEMO-containing structures in fibroblasts carrying the truncated NEMO protein was impaired (as has already been reported for HOIL-1-and HOIP-deficient fibroblasts).
32,33 Furthermore, we showed that colocalization of linear polyubiquitin aggregates and NEMO is severely impaired in fibroblasts carrying the truncated NEMO protein (as in HOIL-1-and NEMO-deficient fibroblasts) treated with IL-1b. Immunoblot analyses confirmed the defect of linear ubiquitination of the truncated NEMO protein.
Lastly, we observed abnormally low expression of all 3 LUBAC subunits in fibroblasts from patients with IP carrying the truncated NEMO species. Based on these results, we suggest that NEMO is essential for stabilization of LUBAC at the protein level.
Otherwise, concerning the other major disease associated with IKBKG mutations, EDA-ID syndrome, we cannot rule out the possibility that the responsible hypomorphic mutations located in the Q134-R256 deleted domain could impair the interaction between NEMO and SHARPIN. Indeed, the panr2 mouse described below carrying the L153P hypomorphic mutation in the Ikbkg gene impairs interaction between NEMO and SHARPIN. 34 Interestingly, a patient with EDA-ID syndrome has been reported to carry a mutation in the human IKBKG gene that affects the same amino acid that is mutated in the panr2 mouse (L153R). 18 Hence one cannot rule out the possibility that the human L153R mutation impairs the NEMO-SHARPIN interaction, as it does in mice. Thus a defect in interaction between NEMO and SHARPIN is an attractive mechanism for both IP and EDA.
Nondegradative linear ubiquitination has recently emerged as a key mediator of NF-kB signaling. This LUBAC-mediated process is involved in the NF-kB pathway responses to both TNF-a and IL-1b. Linear polyubiquitin chains are conjugated to specific Lys residues in NEMO and RIP1. This activity is essential for full NF-kB activation and has a key role in inflammatory and immune responses in both mice and human subjects. [25] [26] [27] [28] [29] Based on findings in both human subjects and mice, the 3 subunits of LUBAC could have functions independent of LUBAC enzymatic activity. For instance, HOIP 2/2 mice are lethal, whereas HOIL-1 2/2 mice are viable and present with immunodeficiency. 35, 36 Sharpin-deficient mice are characterized by chronic proliferative dermatitis and multiorgan inflammation, a phenotype even more different from the 2 others. 37, 38 Moreover, in our immunofluorescence experiments, in addition to their cytoplasmic localization, both NEMO and SHARPIN have been = J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 6 found to interact in the nucleus (Fig 4, B) , which is consistent with the function or functions of SHARPIN independent of the LU-BAC complex.
In human subjects the link between NF-kB and autoinflammation was suggested by the recent demonstration that genetic deficiency of HOIL-1, HOIP, and OTU deubiquitinase with linear linkage specificity proteins (involved in regulation of NEMO linear ubiquitination) arises in patients with atypical autoinflammatory diseases. 32, 33, 39 In mice Sharpin deficiency also results in an autoinflammatory phenotype. 37, 38 However, a direct link between NEMO and autoinflammation in human subjects has not been previously demonstrated. We suggest that autoinflammation, immunodeficiency, and possibly other unidentified symptoms are probably masked through total skewed X-inactivation, a hallmark of female patients with IP. Because NF-kB protects against apoptosis, the total skewed X-inactivation is actually the result of complete elimination shortly after birth of cells with the active X-chromosome bearing the mutated IKBKG allele.
To the best of our knowledge, the link between NF-kB and autoinflammation has been highlighted by publications of female patients with IP displaying Behçet syndrome 40, 41 an authentic multisystem autoinflammatory disease. Moreover, a heterozygous D406V mutation specifically in the IKBKG gene was identified in a female patient with IP with Behçet syndrome. 42 In the latter case the X-inactivation was not completely skewed, which suggests that cells carrying the active mutated X-chromosome had not been completely eliminated, probably because the IKBKG mutation is less severe. Furthermore, an in-frame de novo deletion of 51 amino acids in the NEMO protein was found to result in a deficient interferon regulatory factor 3-mediated response, constituting a novel mechanism for Another IKBKG splice mutation (c.51815G>A) has been reported in patients with a severe form of EDA-ID syndrome. 43 It was also predicted to result in skipping of exons 4 to 6 and thus a similarly truncated form of NEMO protein. In fact, this genotype corresponded to a less harmful nonlethal EDA-ID phenotype in which some normal splicing of the IKBKG mRNA probably persisted. These normal IKBKG mRNA molecules probably provided some residual NF-kB activity and rendered the mutation nonlethal. SHARPIN is a key regulator of immune and inflammatory responses and cytokine production. It is also involved in TNF-a-dependent NF-kB activation and antiapoptotic signaling in hepatocytes. 44 Interestingly, the spontaneous Sharpin-deficient mutation in mice (the cpdm mouse) resulted in epidermal hyperplasia and inflammation with the presence of apoptotic bodies in keratinocytes and increased rates of cell death in the skin (as also observed in Ikbkg 2/2 mice and in patients with IP). 37, 38 Although SHARPIN mutations have never been described in human subjects, they could conceivably be associated with a complex inflammatory phenotype with skin involvement.
In conclusion, we demonstrated that the interaction between a truncated NEMO protein and SHARPIN (but not HOIL-1 or HOIP) was specifically impaired in fibroblasts obtained from a male fetus with IP. Therefore defective linear ubiquitination of NEMO might constitute a hitherto unreported disease mechanism in patients with IP.
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METHODS
Linkage analysis
DNA was extracted from peripheral blood lymphocytes or (for fetus III.4 with IP) fibroblasts through conventional phenol-chloroform purification. Linkage analysis was performed with fluorescent polymorphic microsatellite markers (p39, DXS1073, and F8c). After amplification, PCR products were mixed with the GeneScan 400D ROX size standard ladder (Applied Biosystems, Foster City, Calif) and analyzed with an automatic sequencer (ABI PRISM 3130, Applied Biosystems) by using Genotyper and GeneScan software packages (Applied Biosystems).
X-inactivation analysis
X-inactivation patterns in the patients' peripheral blood lymphocytes were determined by means of PCR amplification of the androgen receptor locus. The procedures for digestion and PCR have been described elsewhere.
E1 PCR products were migrated on an automatic sequencer (ABI PRISM 3130) with GeneScan 400D ROX size standard ladder (Applied Biosystems) and analyzed by using the Genotyper and GeneScan software packages.
Sequencing
All of the IKBKG gene exons and flanking intronic sequences were amplified by using PCR with specific primers. Both DNA strands were sequenced with the Big Dye Terminator Cycle Sequencing Ready Reaction Kit version 3.1 (Applied Biosystems). PCR products were migrated on an ABI PRISM 3130 sequencer (Applied Biosystems) and analyzed with SeqScape Analysis software. Sequence variations of IKBKG were numbered with the adenine of the ATG initiation codon as the first nucleotide (GenBank accession no. NM_003639.3).
RT-PCR and real-time PCR
Total RNAwas isolated from cultured fibroblasts (derived from a male fetus with IP or from healthy control subjects) by using the RNeasy Plus Minikit (Qiagen GmbH, Hilden, Germany), according to the manufacturer's instructions. RNA samples were reverse transcribed into cDNA by using the High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems). Real-time RT-PCR was carried out with the Power SYBR Green PCR Master Mix (Applied Biosystems) on an ABI Prism 7000 (Applied Biosystems) in triplicate. Dissociation analysis for each primer pair and reaction was performed to verify specific amplification.
Structural modeling of the fully dimeric NEMO and its mutant (Del 134-256) complexed with IKK-b and linear or K63-di-ubiquitins
The complex comprising human dimeric NEMO protein (residues 49-419) and linear or K63-di-ubiquitin chains was modeled by using the COILS E2 and PAIRCOIL2 E3 coiled-coil prediction algorithms and the following crystal and nuclear magnetic resonance structures of NEMO fragments: KBD (PDB ID: 3BRV, residues 49-109), HLX2 (PBD ID: 3CL3, residues 193-249), CC2-LZ (PDB ID: 2V4H and 4BWN, residues 257-344), and ZF (PDB ID: 2JVX, residues 392-419). All the regular heptad phases (abcdefg) n within the predicted coiled-coil fragment of NEMO (residues 49-364) and common coiled-coil discontinuities, such as stutters (deletion of 3 residues) and stammers (deletion of 4 residues), were correctly predicted by using PAIRCOIL2 when compared with the heptad phases identified from the available crystal structures by the coiled-coil analysis program SOCKET. E4 For example, this included a stutter at position 103 and a stammer at position 295, respectively. Two other highly predictable discontinuities at positions 203 (a stutter) and 256 (the deletion of 2 residues) were taken into account to accommodate the heptad phases at the KD/HLX2 and HLX2/CC2-LZ junctions. The first model was built by assembling crystal and nuclear magnetic resonance NEMO fragments with the following modeled regions: 110 to 192 (CC1, 83 amino acids), 250 to 256 (7 amino acids), 345 to 364 (20 amino acids), and 365 to 391 (27 amino acids). The long WT CC1 fragment (110-192) and the short mutant CC1 fragment (110-133) were generated with CC Builder by using a radius of 5.07 A, a pitch of 225.8 A, and an interface angle of 26.428. E5 The model of the linker region between the CC2-LZ and ZF domains (365-391) was based on the circular dichroism spectra analyses of the 248 to 344, 248 to 419, and 392 to 419 constructs of human NEMO (unpublished data). This 365 to 391 fragment was generated manually and refined from initial atomic coordinates derived from a I-TASSER-generated model based on a threading algorithm. E6 The NEMO:IKK-b:K63-di-unbiquitin:linear diubiquitin complexes (wild-type and mutant) were built by using homology modeling; the structural templates were the crystal structure of the mouse CC2-LZ complexed with a linear di-ubiquitin chain (PDB ID: 2ZVO) and the modeled NEMO ZF complexed with a K63 di-ubiquitin chain. The short C-terminal fragment of IKK-b (ie, the NEMO-binding domain) bound to the N-terminus of NEMO had already been described as residues S705-Q743 in PDB ID: 3BRV. E7 PyMOL (version 1.7, Schr€ odinger) was used for molecular display and structural figures. Ubiquitin K0 cDNA (where all lysine residues were replaced by arginine, a generous gift from R. Baer, Columbia University, New York, NY) was subcloned into pcDNA3.1. In situ PLAs of LUBAC compounds with wild-type and NEMO-truncated forms in cultured cells
Cell line complementation and transactivation assays
In situ PLAs (Duolink in situ PLA; Olink Biosciences, Uppsala, Sweden) were carried out according to the manufacturer's instructions. Images were acquired and processed with Zeiss LSM-700 and Zen software.
